NCT00485277View on ClinicalTrials.gov

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Breast Cancer
Interventions
BIOLOGICAL

MVA-BN-HER2

Experimental vaccine, subcutaneous injection q3weeks x 3

Trial Locations (2)

94305

Stanford Cancer Center, Stanford

94705

Alta Bates Herrick Hospital Comprehensive Cancer Center, Berkeley

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY